Company research
Adaptive Biotechnologies Corp
CIK 1478320Updated Oct 3, 2026
SecurityADPT · NASDAQ · equity
Name history
Adaptive TCR Corp · through Jun 2, 2011
ADPT price & chart
Loading TradingView…
NASDAQ:ADPT on TradingView ↗About the company
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
In the news
Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026 ↗
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 512,736,000Source | 539,376,000Source | 661,134,000Source | 856,617,000Source |
| Property, Plant and Equipment, NetUSD | 34,107,000Source | 48,616,000Source | 68,227,000Source | 83,447,000Source |
| GoodwillUSD | 118,972,000Source | 118,972,000Source | 118,972,000Source | 118,972,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 70,495,000Source | 47,920,000Source | 65,064,000Source | 90,030,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 50,365,000Source | 41,731,000Source | 37,969,000Source | 40,057,000Source |
| Inventory, NetUSD | 9,820,000Source | 8,440,000Source | 14,448,000Source | 14,453,000Source |
| Assets, CurrentUSD | 300,185,000Source | 283,752,000Source | 410,188,000Source | 562,146,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 13,020,000Source | 11,287,000Source | 11,370,000Source | 9,440,000Source |
| Operating Lease, Right-of-Use AssetUSD | 40,616,000Source | 45,767,000Source | 52,096,000Source | 80,763,000Source |
| Other Assets, NoncurrentUSD | 1,207,000Source | 2,287,000Source | 3,591,000Source | 2,064,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 287,735,000Source | 336,891,000Source | 352,856,000Source | 392,519,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 15,000Source | 14,000Source | 14,000Source | 14,000Source |
| Additional Paid in CapitalUSD | 1,581,848,000Source | 1,506,353,000Source | 1,452,502,000Source | 1,387,349,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,363,323,000Source | -1,303,824,000Source | -1,144,332,000Source | -919,082,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 253,000Source | 166,000Source | 215,000Source | -4,116,000Source |
| Stockholders' Equity Attributable to ParentUSD | 218,793,000Source | 202,709,000Source | 308,399,000Source | 464,165,000Source |
| Liabilities and EquityUSD | 512,736,000Source | 539,376,000Source | 661,134,000Source | 856,617,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 89,915,000Source | 98,053,000Source | 88,015,000Source | 109,788,000Source |
| Operating Lease, Liability, CurrentUSD | 8,920,000Source | 10,239,000Source | 9,384,000Source | 9,230,000Source |
| Accounts Payable, CurrentUSD | 6,467,000Source | 7,265,000Source | 7,719,000Source | 8,084,000Source |
| Operating Lease, Liability, NoncurrentUSD | 70,228,000Source | 79,148,000Source | 89,388,000Source | 98,772,000Source |
| Other Liabilities, NoncurrentUSD | 20,000Source | 20,000Source | — | — |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 6,208,000Source | -224,000Source | -121,000Source | -67,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 7,700,000Source | 8,157,000Source | 8,597,000Source | 12,424,000Source |
| Deferred Tax Liabilities, NetUSD | 0Source | 0Source | 0Source | 0Source |
| Long-term Debt, Current MaturitiesUSD | 4,642,000Source | 865,000Source | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 126,566,000Source | 132,414,000Source | 130,660,000Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -59,457,000Source | -159,595,000Source | -225,304,000Source | -200,368,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 51,483,000Source | 53,610,000Source | 62,908,000Source | 55,477,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 8,646,000Source | 3,744,000Source | -2,032,000Source | 22,648,000Source |
| Increase (Decrease) in InventoriesUSD | 998,000Source | -5,372,000Source | 2,838,000Source | -817,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -45,986,000Source | -95,212,000Source | -156,324,000Source | -183,945,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 37,950,000Source | 77,792,000Source | 129,647,000Source | 2,905,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 2,959,000Source | 3,664,000Source | 10,697,000Source | 16,349,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 30,403,000Source | 241,000Source | 2,245,000Source | 132,265,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 22,367,000Source | -17,179,000Source | -24,432,000Source | -48,775,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 12,638,000Source | 8,864,000Source | 8,985,000Source | 494,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 51,483,000Source | 53,610,000Source | 62,908,000Source | 55,477,000Source |
| Amortization of Intangible AssetsUSD | 1,699,000Source | 1,703,000Source | 1,699,000Source | 1,699,000Source |
| DepreciationUSD | 16,134,000Source | 17,553,000Source | 20,532,000Source | 19,221,000Source |
| General and Administrative ExpenseUSD | 72,701,000Source | 72,806,000Source | 83,934,000Source | 88,527,000Source |
| GoodwillUSD | 118,972,000Source | 118,972,000Source | 118,972,000Source | 118,972,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets, Finite-livedUSD | 0Source | 0Source | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Inventory Write-downUSD | 563,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -59,499,000Source | -159,492,000Source | -225,250,000Source | -200,191,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | 42,000Source | -103,000Source | -54,000Source | -177,000Source |
| Operating Lease, ExpenseUSD | 9,200,000Source | 9,600,000Source | 11,400,000Source | 12,400,000Source |
| Operating Lease, Impairment LossUSD | — | — | 21,200,000Source | — |
| Proceeds from Contributed CapitalUSD | 12,524,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | 17,879,000Source | 241,000Source | 2,245,000Source | 7,890,000Source |
| Restructuring CostsUSD | — | 9,200,000Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 276,976,000Source | 178,957,000Source | 170,276,000Source | 185,308,000Source |
| Cost of RevenueUSD | 71,359,000Source | 72,080,000Source | 75,553,000Source | 57,909,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Operating Income (Loss)USD | -57,123,000Source | -162,549,000Source | -227,035,000Source | -200,186,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -59,457,000Source | -159,595,000Source | -225,304,000Source | -200,368,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | 42,000Source | -103,000Source | -54,000Source | -177,000Source |
| Net Income (Loss) Attributable to ParentUSD | -59,499,000Source | -159,492,000Source | -225,250,000Source | -200,191,000Source |
| Earnings Per Share, BasicUSD per share | -0.39Source | -1.08Source | -1.56Source | -1.4Source |
| Earnings Per Share, DilutedUSD per share | -0.39Source | -1.08Source | -1.56Source | -1.4Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 151,721,939Source | 147,101,648Source | 144,383,294Source | 142,515,917Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 151,721,939Source | 147,101,648Source | 144,383,294Source | 142,515,917Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 1,699,000Source | 1,703,000Source | 1,699,000Source | 1,699,000Source |
| Costs and ExpensesUSD | 334,099,000Source | 341,506,000Source | 397,311,000Source | 385,494,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 16,000,000Source | 19,256,000Source | — | — |
| General and Administrative ExpenseUSD | 72,701,000Source | 72,806,000Source | 83,934,000Source | 88,527,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -59,472,000Source | -159,635,000Source | -225,335,000Source | -200,427,000Source |
| Interest and Other IncomeUSD | 9,444,000Source | 14,534,000Source | 15,531,000Source | 4,056,000Source |
| Interest ExpenseUSD | 11,778,000Source | 11,580,000Source | 13,800,000Source | 4,238,000Source |
| Operating Lease, ExpenseUSD | 9,200,000Source | 9,600,000Source | 11,400,000Source | 12,400,000Source |
| Research and Development ExpenseUSD | 93,769,000Source | 102,953,000Source | 122,117,000Source | 141,756,000Source |
| Restructuring CostsUSD | — | 9,200,000Source | — | — |
| Selling and Marketing ExpenseUSD | 94,571,000Source | 84,759,000Source | 88,579,000Source | 95,603,000Source |
Filing attachments
adpt-ex99_1.htm · 8-K · 2026-07-29
EX-99.1 2 adpt-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results SEATTLE, Jul. 29, 2026 (GLOBE NEWSWIRE) - Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2026. “We deliver…
Read attachment ↗d28937dex41.htm · 8-K · 2026-06-22
EX-4.1 2 d28937dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 EXECUTION VERSION ADAPTIVE BIOTECHNOLOGIES CORPORATION and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of June 22, 2026 0% Convertible Senior Notes due 2031 TABLE OF CONTENTS Page Article 1. Defini…
Read attachment ↗d28937dex991.htm · 8-K · 2026-06-22
EX-99.1 5 d28937dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibility Additional proceeds used to pay for the capped call with a premium of 100% and to repurchase $25 million of common stock to reduce potential dilution Remaining capital to be used for general corporate purposes and opport…
Read attachment ↗d65233dex991.htm · 8-K · 2026-06-15
EX-99.1 2 d65233dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibility Additional proceeds used to pay for the capped call with a premium of at least 75% and to repurchase up to $25 million of common stock to reduce potential dilution Remaining capital to be used for general corporate purposes and o…
Read attachment ↗d65233dex992.htm · 8-K · 2026-06-15
EX-99.2 3 d65233dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses MRD has scaled into a profitable, category-leading MRD diagnostics business, while Immune Medicine has built a differentiated discovery platform powered by proprietary immune data and AI SEATTLE, June 15, 2026 (GLOBE NEWSWIRE) - Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company focused on translatin…
Read attachment ↗adpt-ex99_1.htm · 8-K · 2026-05-05
EX-99.1 2 adpt-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 Adaptive Biotechnologies Reports First Quarter 2026 Financial Results SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) - Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2026. “We delivere…
Read attachment ↗